(ve doe LIZ ue mab)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted, Intravenous [preservative free]:
Entyvio: 300 mg (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]
Brand Names: U.S.
- Gastrointestinal Agent, Miscellaneous
- Monoclonal Antibody
- Monoclonal Antibody, Selective Adhesion-Molecule Inhibitor
Vedolizumab is a humanized monoclonal antibody that binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn disease.
Vd: 5 L
25 days (serum, at 300 mg dosage)
Use: Labeled Indications
Crohn disease: Treatment of moderately to severely active Crohn disease in patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Ulcerative colitis Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response with, were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Serious or severe hypersensitivity to vedolizumab or any component of the formulation
Note: Prior to initiating treatment, all patients should be brought up to date with all immunizations according to current immunization guidelines.
Crohn disease or ulcerative colitis: IV: 300 mg at 0, 2, and 6 weeks and then every 8 weeks thereafter. Discontinue therapy in patients who show no evidence of therapeutic benefit by week 14.
Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Discontinue use with jaundice or signs/symptoms of hepatic injury.
Reconstitute at room temperature with 4.8 mL of sterile water for injection. Gently swirl vial for at least 15 seconds; do not vigorously shake or invert. Allow the solution to sit for up to 20 minutes at room temperature to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within 30 minutes. Solution should be clear or opalescent, colorless to light brownish yellow and free of visible particulates. Do not administer reconstituted solution showing uncharacteristic color or containing particulates.
Prior to withdrawing the reconstituted vedolizumab solution from the vial for dilution, gently invert vial 3 times. Add the 5 mL (300 mg) of reconstituted vedolizumab solution to 250 mL of sterile sodium chloride 0.9% and gently mix the infusion bag. Once reconstituted and diluted, use the infusion solution as soon as possible.
IV: Infuse over 30 minutes. Do not administer by IV push or bolus. Following infusion , flush with 30 mL of sterile 0.9% sodium chloride injection. Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; discontinue if a reaction occurs.
Refrigerate unopened vials at 2°C to 8°C (36ºF to 46ºF). Retain in original package to protect from light. Following reconstitution and dilution, the infusion solution may be stored for up to 4 hours at 2°C to 8°C (36ºF to 46ºF). Do not freeze. Discard any unused portion.
Anti-TNF Agents: May enhance the adverse/toxic effect of Vedolizumab. Avoid combination
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. Avoid combination
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Natalizumab: Vedolizumab may enhance the adverse/toxic effect of Natalizumab. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modification
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modification
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Monitor therapy
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Avoid combination
Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Monitor therapy
Travelers' Diarrhea and Cholera Vaccine: Vedolizumab may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine. Management: Administer travelers' diarrhea andl cholera vaccine prior to initiation of therapy with vedolizumab. Consider therapy modification
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Avoid combination
Central nervous system: Headache (12%)
Immunologic: Antibody development (4% to 13%; neutralizing: 2%)
Neuromuscular & skeletal: Arthralgia (12%)
Respiratory: Nasopharyngitis (13%)
1% to 10%:
Central nervous system: Fatigue (6%)
Dermatologic: Pruritus (3%), skin rash (3%)
Gastrointestinal: Nausea (9%)
Hepatic: Increased serum ALT (≥3 x ULN: <2%), increased serum AST (≥3 x ULN: <2%)
Infection: Influenza (4%)
Neuromuscular & skeletal: Back pain (4%), limb pain (3%)
Respiratory: Upper respiratory tract infection (7%), cough (5%), bronchitis (4%), oropharyngeal pain (3%), sinusitis (3%)
Miscellaneous: Fever (9%), infusion related reaction (4%)
<1% (Limited to important or life-threatening): Hepatitis, hypersensitivity reaction, infection (including anal abscess, sepsis, tuberculosis, salmonella sepsis, listeria meningitis, giardiasis, cytomegaloviral colitis), malignant neoplasm (excluding dysplasia and basal cell carcinoma)
Concerns related to adverse effects:
• Hypersensitivity reactions: Hypersensitivity reactions have been reported including anaphylaxis. Allergic reactions including dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed. Symptom onset may vary from during the infusion, immediately post-infusion, to several hours post-infusion. If serious reactions occur, discontinue administration immediately.
• Infections: Use may be associated with an increased risk for developing infections; most commonly reported infections included upper respiratory and nasal mucosa. Serious infections have also been reported in patients treated, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. Therapy is not recommended in patients with uncontrolled, active, severe infections. If a patient develops a serious infection, consider discontinuing therapy. Use with caution in patients with a history of recurring severe infections. Screening for tuberculosis should be considered.
• Liver injury: Elevations of transaminase and/or bilirubin have been reported in patients receiving vedolizumab. Discontinue therapy in patients with jaundice or other evidence of significant liver injury such as fatigue, anorexia, right upper abdominal discomfort, or dark urine.
• Progressive multifocal leukoencephalopathy: Integrin receptor antagonists have been associated with progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system caused by the John Cunningham (JC) virus. Monitor patients for any new onset or worsening of neurological signs and symptoms including progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Symptoms may progress over days to weeks and can lead to death or severe disability in weeks to months. If PML is suspected withhold therapy and refer to a neurologist; if confirmed, discontinue therapy permanently.
• Immunizations: Patients should be brought up to date with all immunizations according to immunization guidelines before initiating therapy. Live vaccines should not be given concurrently unless the benefits outweigh the risks; there are no data on the secondary transmission of infection by live vaccines with vedolizumab. Non-live vaccines may be given concurrently.
Observe patients during infusion (until complete) and monitor for hypersensitivity reactions; LFTs; tuberculosis screening according to local practice; signs/symptoms of infection; any new onset or worsening of neurological signs and symptoms
Pregnancy Risk Factor
Adverse events have not been observed in animal reproduction studies. Monoclonal antibodies are transported across the placenta in a linear fashion as pregnancy progresses, with the largest amount transferred during the third trimester. Any adverse pregnancy effect would likely be greater during the second and third trimesters of pregnancy.
Health care providers are encouraged to enroll women exposed to vedolizumab during pregnancy in a pregnancy exposure registry. Information about the registry can be obtained by calling 1-877-825-3327.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience back pain, common cold symptoms, joint pain, nausea, rhinitis, pharyngitis, extremity pain, or loss of strength and energy. Have patient report immediately to prescriber signs of infection, signs of infusion reaction, signs of liver problems (dark urine, feeling tired, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin or eyes), shortness of breath, wheezing, coughing, dizziness, flushing, tachycardia, arrhythmia, severe headache, or signs of progressive multifocal leukoencephalopathy (confusion, depression, trouble with memory, behavioral changes, change in strength on one side, trouble speaking, change in balance, or vision changes) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about vedolizumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 12 Reviews – Add your own review/rating
Other brands: Entyvio